The PCSK9-REACT study (association of PCSK9 serum levels and platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor) by ATLANTIS-ACS (association between the antiplatelet drug efficacy/safety and platelet function in patients treated with novel platelet inhibitors due to an acute coronary syndrome) further highlighted the significant and direct relationship of higher PCSK9 levels and higher platelet reactivity [70]. Here, PCSK9 is linked to acute coronary syndrome.